Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Design and in vitro evaluation of a novel controlled onset extended-release delivery system of metoprolol tartrate.
Res Pharm Sci
April 2016
Department of Pharmaceutics, School of Pharmacy and pharmaceutical Sciences and Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
Blood pressure rises rapidly upon awakening and maybe responsible, in part, for the increased incidence of myocardial infarction and stroke during the morning hours. The aim of the present study was, therefore, to develop a novel chronotherapeutic formulation of metoprolol tartrate (MT) for night time dosing providing maximum effect in the morning hours. Core tablets contained MT, sodium chloride, lactose, Avicel(®) and starch.
View Article and Find Full Text PDFBedtime hypertension chronotherapy: concepts and patient outcomes.
Curr Pharm Des
September 2015
Department of Biomedical Engineering, Cockrell School of Engineering, The University of Texas at Austin, 1 University Station C0800, Austin, Texas 78712-0238.
Recent findings indicate cardiovascular disease (CVD) risk is best predicted by asleep systolic blood pressure (SBP), and lowering it by scheduling ≥1 conventional long-acting hypertension medications, alone or in combination, at bedtime significantly lessens vascular-associated risks. Some 20 years ago, four controlled-onset extended-release drug-delivery systems incorporating a calcium channel or β-blocker, with the treatment goal specifically being attenuation of morning rather than asleep BP, were conceived as one type of bedtime hypertension chronotherapy. However, the CONVINCE outcomes trial failed to substantiate the merit of targeting morning and daytime BP to decrease CVD risk.
View Article and Find Full Text PDF[Preparation of verapamil hydrochloride controlled-onset extended-release pellets and its pharmacokinetics in dogs].
Yao Xue Xue Bao
August 2006
Institute of Pharmaceutics, China Pharmaceutical University, Nanjing 210038, China.
Aim: To prepare verapamil hydrochloride controlled-onset extended-release pellets (VH-COERP) and study its release behavior in vitro. To compare the pharmacokinetic characteristics and bioavailability in six Beagle dogs after oral administration of VH-COERP and verapamil hydrochloride delayed-release pellets (VH-DRP) as reference.
Methods: The core of VH-COERP were prepared in the fluidized bed (mini-glatt) by spraying water solution containing drugs onto sucrose-starch pellets with hydroroxy propyl methyl cellulose (HPMC) as the inner coating swelling layer and ethylcellulouse aqueous dispersion as the outer coating controlled layer.
A pharmacodynamic model of the effects of controlled-onset extended-release verapamil on 24-hour ambulatory blood pressure.
Int J Clin Pharmacol Ther
April 2005
Center for Clinical Pediatric Pharmacology & Pharmacogenetics, Nemours Children's Clinic, 807 Nira Street, Jacksonville, FL 32207, USA.
Objective: To formulate and evaluate a pharmacodynamic model that characterizes the effects of S-verapamil on the circadian 24-hour ambulatory blood pressure (ABP).
Methods: ABP was recorded in 19 hypertensive patients off drug, and following administration of the targeted dose of COER-V given once daily for at least 30 days. Blood samples were collected after the last dose for determination of the pharmacokinetic of S-verapamil.
Controlled-onset extended-release verapamil was not equivalent to standard therapy for preventing cardiovascular disease.
ACP J Club
December 2003
University of Florida College of Medicine, Gainesville, Florida, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!